Clinical trial

Docetaxel Alone or in Combination With Enzalutamide for mCRPC Previously Treated With Abiraterone at mHSPC Stage

NCT05627752

Study summary

ClinicalTrials.gov

Docetaxel Alone or in Combination With Enzalutamide for mCRPC Previously Treated With Abiraterone at mHSPC Stage

Design: INTERVENTIONAL · Status: UNKNOWN · Phase: PHASE2, PHASE3

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Mapped RxNorm record Enzalutamide 40 MG Normalized identity: enzalutamide 40 MG View linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Docetaxel injection Normalized identity: docetaxel Injection View linked drug · Find medicine records · Find other trials using this name

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2024-06-01

PhasePHASE2 / PHASE3

Conditions

Prostate Cancerverified · MONDO: prostate cancer

Castrate Resistant Prostate Cancerunresolved

Interventions

Enzalutamide 40 MGDRUG · verified · RxNorm: enzalutamide 40 MG

Docetaxel injectionDRUG · verified · RxNorm: docetaxel Injection

Sponsors & collaborators

Zhongnan Hospitallead sponsor

Mapped research locations

WuhanHubei, China2

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05627752 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.